Ampliphi Biosciences (APHB) Stock Price, News & Analysis

Company Overview

Ampliphi Biosciences, Inc. is a clinical‐stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of novel therapies to prevent and treat life‐threatening drug‐resistant infections. The company’s core mission is to address the growing global threat of antibiotic resistance by advancing first‐in‐class and best‐in‐class antibacterial agents through late‐stage clinical trials.

The company’s lead product candidate, exeporfinium chloride (XF-73), is a pioneering topical antibacterial designed for pre‐operative nasal decolonization of Staphylococcus aureus in patients undergoing high‐risk surgical procedures. XF-73 has demonstrated the potential to significantly reduce surgical site infections by targeting nasal carriage of S. aureus, including methicillin‐resistant strains. Beyond XF-73, Ampliphi is expanding its pipeline through its proprietary drug conjugate platform, which seeks to create novel antibacterial compounds active against a broad spectrum of Gram‐negative and Gram‐positive pathogens.

Founded on a scientific foundation of antimicrobial innovation, Ampliphi Biosciences emerged following the strategic divestiture of earlier antifungal programs to a major pharmaceutical partner. The company operates primarily in North America and is preparing to extend its global footprint through strategic collaborations and licensing agreements. Ampliphi is supported by a leadership team with deep expertise in infectious disease drug development, manufacturing, and regulatory affairs, positioning the company to advance its candidates toward commercialization and address critical unmet needs in patient care.

Key Stats

• Today's Range: $3.17 to $3.29
• 50-Day Range: $2.41 to $3.21
• 52-Week Range: $0.15 to $1.37
• Volume: 11,428 shs
• Average Volume: 842,200 shs
• Market Capitalization: $106.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

APHB Stock Analysis - Frequently Asked Questions

How have APHB shares performed this year?

Ampliphi Biosciences' stock was trading at $1.9490 at the start of the year. Since then, APHB shares have increased by 62.6% and is now trading at $3.17.

How were Ampliphi Biosciences' earnings last quarter?

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) released its earnings results on Monday, March, 25th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.07.

How do I buy shares of Ampliphi Biosciences?

Shares of APHB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ampliphi Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ampliphi Biosciences investors own include Navios Maritime Partners (NMM), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Protalix BioTherapeutics (PLX), Athersys (ATHX) and Corbus Pharmaceuticals (CRBP).

Company Calendar

• Last Earnings: 3/25/2019
• Today: 10/13/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NYSEAMERICAN:APHB
• Previous Symbol: AMEX:APHB
• CIK: 921114
• Web: www.ampliphibio.com
• Phone: +1-804-8272524
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,469,000
• Free Float: N/A
• Market Cap: $106.10 million
• Optionable: Not Optionable
• Beta: N/A